BEHAVOX
16.5.2022 15:05:13 CEST | Business Wire | Press release
Behavox , which provides a suite of security products that help compliance, HR, and security teams protect their company and colleagues from bad actors, today announced that its academic research paper on artificial intelligence “Continual learning using lattice-free MMI for speech recognition” has been accepted by the International Conference on Acoustics, Speech, and Signal Processing (ICASSP). ICASSP is the world's largest and most comprehensive technical conference focused on signal processing and its applications. Behavox presented this paper in Singapore for IEEE ICASSP 2022 on May 9, 2022.
“Sometimes scientists do research for science’s sake and society is unlikely to see benefits in the near future. In contrast, we pushed science to a new frontier to find a solution to a current problem,” said Behavox CTO Joseph Benjamin. “We are honored to have received recognition from such a prestigious conference and are very proud of our team and the work they did.”
The paper, written by Behavox’s Machine Learning team, addresses challenges of continuously improving speech recognition systems in privacy-preserving settings. This research directly links to Behavox’s R&D approach for providing customers with the best transcription quality in the financial market. In FinTech, the language and the data that Behavox systems have to reliably process rapidly change over time, with the rise of cryptocurrencies and video communications being but two examples.
Consequently, machine learning models must be frequently updated on relevant data. To make such updates possible without undermining data privacy, the model should be able to gradually improve inside secure client environments without access to historical data and data from other customers. This is a challenging problem in machine learning due to catastrophic forgetting, where after improving on a specific type of data, the model starts to perform badly on previously learned data.
The Behavox ICASSP paper contributes to the field of continual learning for speech recognition. Authors propose a novel algorithm that extends and refines the commonly used Learning Without Forgetting (LWF) technique, which relies on a regularization term and forces neural networks to reduce forgetting. More specifically, the authors designed a novel sequence level neural network training loss that can be used instead of conventional point-wise LWF. They demonstrated a significant reduction of forgetting when the neural network is fine-tuned sequentially on various accents and speech styles.
Behavox has found that the use of voice platforms has increased 94 percent year-over-year and that on average almost a third of all workplace communications take place via phone or video conference calls.
This technique has already been successfully applied to its Danish system, where the collaborative work of Behavox linguists, the machine learning team, and a customer allowed Behavox to build its first Danish transcription system that reliably works on banking data.
About Behavox
Behavox provides a suite of security products that help compliance, HR, and security teams protect their company and colleagues from bad actors.
Through AI-powered analysis of all corporate communications data, including email, instant messaging, voice, and video conferencing platforms, Behavox helps organizations identify illegal, immoral, and malicious behavior in the workplace.
Founded in 2014, Behavox is headquartered in Montreal and has offices in New York City, London, Seattle, Singapore, and Tokyo.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220513005069/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
